Carl Johan Bertil Sundberg

KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine.

Feelgood Svenska AB engages in the provision of healthcare services. Its operations include occupational health, training, primary care, physical education, and physiotherapy. The firm serves businesses, organizations, and private individuals. The company was founded in 1995 and is headquartered in Stockholm, Sweden.

Cobra Biologics Holding AB manufactures biologics and pharmaceuticals for pre-clinical, clinical, and commercial products. Its services include gene therapies and vaccines, products for testing, process development and scale up of vaccine products, production of sterile drug products, and process development and production, automation, and traceability of programs. The company was founded in 2011 and is headquartered in S?dert?lje, Sweden.

Karolinska Investment Fund KB is a healthcare-focused fund based in Stockholm. Targeted portfolio companies are pharmaceutical, biotechnology and medical technology companies located in Sweden.

Global Genomics AB used to discovers disease genes, drug targets and disease-associated biomarkers. It was also developing and out-licenses proprietary tools in functional genomics that provide insight into healthy, diseased or drug-treated cells. The company was founded by Patrik Ernfors & Sten Linnarsson in September, 2000 and was located in Stockholm, Sweden.

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.

Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden.